Details
Stereochemistry | MIXED |
Molecular Formula | C24H33NO3 |
Molecular Weight | 383.5237 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C23
InChI
InChIKey=KBAFPSLPKGSANY-UHFFFAOYSA-N
InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3
Molecular Formula | C24H33NO3 |
Molecular Weight | 383.5237 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. The drug act as a selective antagonist of 5-HT2 receptors. Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftoling, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax. Praxilene belongs to a group of medicines known as ‘metabolic activators’. These are used to treat different types of blood circulation problems. Praxilene allows the body to make better use of the oxygen in your blood. Praxilene is used to treat the following symptoms: cramp-like pains; cramps in legs at night; severe pain in r legs when people are resting (rest pain); pale or blue fingers or toes which get worse when it is cold; numbness, tingling or burning feelings in the fingers or toes (Raynaud’s syndrome or acrocyanosis); open sores on the legs or feet (trophic ulcers); poor circulation caused by diabetes (diabetic arteriopathy).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095200 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1369714 |
0.06 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Praxilene Approved UseUnknown Launch Date2016 |
PubMed
Title | Date | PubMed |
---|---|---|
New treatment options in intermittent claudication: the US experience. | 2001 Apr |
|
Naftidrofuryl in quality of life (NIQOL). A Belgian study. | 2001 Dec |
|
[Intermittent claudication. Walking plus vasoactive drug treatment]. | 2001 Jul 5 |
|
Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents. | 2001 May |
|
Effect of naftidrofuryl on intramuscular partial oxygen pressure (pO2) prior to, during and after physical load on the treadmill in apparently healthy subjects. | 2002 |
|
Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. | 2002 Mar |
|
Naftidrofuryl-induced liver injury. | 2003 Jun |
|
Naftidrofuryl: a review of its use in the treatment of intermittent claudication. | 2005 |
|
[Inpatient infusion treatment for acute tinnitus with and without adjuvant psychotherapeutic intervention. A comparison of psychological effectiveness]. | 2006 Oct |
|
Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate. | 2009 Aug |
|
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. | 2009 Mar 10 |
|
Pharmacologic therapy for intermittent claudication. | 2009 May |
|
Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss. | 2009 Oct 7 |
|
Fatal intoxication with naftidrofuryl. | 2009 Sep |
|
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
The recommended dose is one or two capsules (100 mg naftidrofuryl oxalate) three times a day, for a minimum of three months
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7863151
After culture in a rat serum enriched with naftidrofuryl at concentration of 20 uM, we observed a protective effect of this drug toward the disruption of axonal microtubules by vinka alkaloids
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:48:37 GMT 2023
by
admin
on
Sat Dec 16 15:48:37 GMT 2023
|
Record UNII |
42H8PQ0NMJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C04AX21
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
||
|
WHO-VATC |
QC04AX21
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
42H8PQ0NMJ
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
m7707
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB13588
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
Naftidrofuryl
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
SUB09130MIG
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
4417
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
250-572-2
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
2177
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
D009257
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL1620794
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
DTXSID3023344
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
31329-57-4
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
1870
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
100000084457
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
C87212
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | |||
|
7236
Created by
admin on Sat Dec 16 15:48:38 GMT 2023 , Edited by admin on Sat Dec 16 15:48:38 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|